ResMed Acquires Laboratoires Narval

SAN DIEGO -

- Expands Current Therapy Range and Patient Reach through Acquisition

ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced today that it has acquired Laboratoires Narval. Based in France, Laboratoires Narval manufactures and distributes the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) that offers a solution to patients for snoring and obstructive sleep apnea (OSA), especially for those with mild OSA. With this acquisition, ResMed adds another therapy to supplement its existing positive airway pressure-based solutions, providing a broader offering for this patient group. ResMed plans to commercialize this device in selected European markets.

“Obstructive sleep apnea is a serious disease that, left untreated, can have significant long-term impacts on the cardiovascular system, as well as impacts on other serious and chronic health issues,” said Michael Farrell, Senior Vice President of the Sleep Business Unit, ResMed. “The gold-standard therapy for obstructive sleep apnea is continuous positive airway pressure (CPAP) therapy. ResMed will now be able to provide an alternative solution for patients with mild obstructive sleep apnea as well as those with snoring. In addition, in France, there is reimbursement for MRD use as a second line treatment for severe OSA for those who are non-compliant on or refuse CPAP. We have found a good match in Narval as we both strive for clinical excellence and quality therapy solutions through market-leading innovation, education and service.”

The Narval O.R.M. device is an effective and clinically proven mandibular repositioning device with unique features such as a patented articulation to ensure a physiological position of the temporomandibular joint (TMJ) at night, developed with unique computer-aided design software that optimizes the design for each patient, and a scalable computer-aided manufacturing process (CAD/CAM).

“As part of ResMed, we are excited to further broaden the use of our novel and clinically proven O.R.M. device and to further develop our leading CAD/CAM technology,” said Fabrice Paublant, Chief Executive Officer, Laboratoires Narval. “The team at Narval looks forward to working closely with ResMed to expand the marketing and distribution for our technology within Europe.”

Sleep apnea is the most common sleep disorder, yet it remains vastly undiagnosed. Sleep apnea is closely linked with diabetes, obesity, high blood pressure, heart failure and stroke. In obstructive sleep apnea, breathing is interrupted by a physical block to airflow, despite the effort to breathe. Obstructive sleep apnea is a very common disease that affects millions of people worldwide. Recent clinical studies have concluded that left untreated, sleep apnea can increase the risk of dying early (www.msnbc.msn.com/id/32461830/ns/health-more_health_news/) by as much as 46%.*

About ResMed

ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com

About Laboratoires Narval

Laboratoires Narval’s mission is to provide innovative therapeutic solutions to treat respiratory sleep disorders. Laboratoires Narval is a French company based in Lyon, created by Ludovic Baratier, the inventor of the O.R.M. device, Laurent Viviani, and Fabrice Paublant and backed by Aurinvest and S.H.A.M. investors. For more information on Laboratoires Narval, please visit www.laboratoiresnarval.com

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company’s future revenue, earnings or expenses, new product development and new markets for the Company’s products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company’s Web site.

*Sleep-Disordered Breathing and Mortality: A Prospective Cohort Study. Naresh M. Punjabi et al. PLoS Medicine. August 2009/ Volume 6/ Issue 8/ e1000132

Source: ResMed Inc.

Global Investor Relations and US/Australian Media, Constance Bienfait of ResMed Inc., San Diego, +1-858-836-5971, or European Media, Anne Reiser of ResMed France, +33-426100-268